Amneal Pharmaceuticals (AMRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$17.44-2.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · AMRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 22.8% |
| Our one-year growth estimate | diamond | 7.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 15.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 23 industry peers
AMRX — credit agreement
Dated 2026-08-10
by reference. First Amendment to the Third Amended and Restated Stockholders Agreement In connection with the consummation of the Acquisition, on the Closing Date, Amneal entered into a First Amendment to the Third Amended and Restated Stockholders Agreement (the “Stockholders Agreement Amendment”) with Vikram Patel, in his capacity as the Amneal Group Representative (as defined in the Third Amended and Restated Stockholders Agreement, dated November 7, 2023, by and among Amneal, Amneal Inter…
Why it matters: Lowering debt would help keep finances stable. It would also make investors trust Amneal's growth.
Supportive ifNet leverage decreases below 3.0x by 2028 as planned.
Worry ifNet leverage stays above 3.0x. This shows challenges in managing debt levels.
Why it matters: Strong revenue growth signals continued momentum and supports the raised guidance for 2026.
Supportive ifQ3 revenue growth exceeds 10% year-over-year compared to Q3 2025.
Worry ifQ3 revenue growth is below 5% year-over-year.
Why it matters: Better cash flow shows stronger financial health. It helps support growth plans.
Supportive ifOperating cash flow exceeds $400 million for the full year 2026.
Worry ifOperating cash flow remains below $350 million for the full year.
Why it matters: Raising guidance shows strong business growth. This shows Amneal's potential to grow.
Supportive ifManagement raises guidance for 2026 again. This means more money or adjusted EBITDA.
Worry ifManagement keeps or lowers guidance for the year. This is due to unexpected problems.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$135 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $313 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,225 loss on $10,000 · 22.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Completing the Kashiv deal will boost Amneal's biosimilars platform and growth.
Supportive ifThe deal closes as planned. All regulatory approvals are received.
Worry ifThe deal faces delays or does not get the needed approvals.
Why it matters: Better margins mean the company is more efficient and controls costs well.
Supportive ifAdjusted EBITDA margin is over 25% in Q2 2026.
Worry ifAdjusted EBITDA margin stays below 25% in Q2 2026.
Why it matters: If revenue guidance goes up, it shows good performance. It also shows management's confidence.
Supportive ifManagement raises 2026 revenue guidance to more than $3.20 billion.
Worry ifManagement keeps or lowers revenue guidance to less than $3.10 billion.
Why it matters: Shareholder approval is important for Amneal to complete the Kashiv deal. This could help growth in biosimilars.
Supportive ifAmneal gets shareholder approval for the deal before closing in the second half of 2026.
Worry ifShareholders reject the deal or delay the vote.
Why it matters: Better cash flow would show stronger financial health and efficiency.
Supportive ifOperating cash flow exceeds $350 million in Q3 2026.
Worry ifOperating cash flow remains below $350 million in Q3 2026.
Why it matters: Strong growth in the Specialty segment would help Amneal compete better and grow.
Supportive ifSpecialty segment revenue growth reported above 20% in Q2 2026.
Worry ifSpecialty segment revenue growth reported below 15% in Q2 2026.
Why it matters: Steady revenue growth shows strong demand for Amneal's products. It supports their growth plans.
Supportive ifQ2 2026 net revenue is over $750 million, showing growth from Q1 2026.
Worry ifQ2 2026 net revenue reported below $750 million, showing a slowdown in growth.